Krystal Biotech (NASDAQ:KRYS) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec). The new approval broadens the patient eligibility for Vyjuvek to include individuals with dystrophic epidermolysis bullosa from birth. It also allows patients ...